RecruitingPhase 1NCT07566572

A Study of BGM0504 Tablets in Healthy Chinese Subjects

A Randomized, Open-label, Multiple-dose Phase I Clinical Study to Evaluate the Effect of a High-fat Meal and Different Dosing Conditions on the Pharmacokinetics of BGM0504 Tablets in Healthy Chinese Participants.

Sponsor

BrightGene Bio-Medical Technology Co., Ltd.

Enrollment

144 participants

Start Date

Mar 26, 2026

Study Type

INTERVENTIONAL

Conditions

Chinese Healthy Volunteers

Summary

A randomized, open-label, multiple-dose study to evaluate the effects of high-fat meals and different administration conditions (including water intake and fasting time) on the pharmacokinetics of BGM0504 tablets at a dose of 20mg in healthy Chinese participants and to assess its safety and tolerability.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BGM0504 tablets for people with chinese healthy volunteers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBGM0504 tablets

Administered p.o.

Locations(1)

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07566572